Medizinische Fachkreise

HEARTWARE HVAD SYSTEM

Advanced Heart Failure Management

PROVEN. TRUSTED. COMMITTED.

Forty-two percent of all heart transplants are bridged to transplant with a ventricular assist device (VAD).¹ The Medtronic commitment to advance the treatment of end-stage heart failure has never been stronger.

The HeartWare™ HVAD™ System is the most widely studied implanted centrifugal ventricular device.^2-5

Over 2,000 patients are enrolled in HeartWare HVAD trials.

As many as 350 hospitals trust the HeartWare HVAD System. It's used in 47 countries and serves more than 13,000 patients worldwide.^*

We continually learn and innovate, further advancing the treatment of end-stage heart failure. We are always striving to improve patient outcomes and the clinical experience of your practice.

UNIQUELY DESIGNED

The HeartWare™ HVAD™ Pump is engineered for reliability and durability.

The pump's passive maglev with hydrodynamic bearings means there's no need for electronic sensors or mechanical bearings. This results in a less complex system that eliminates friction, heat, and component wear.⁶

Dual motor stators enhance efficiency and provide redundancy to rotate the impeller. This design maintains support even in single-motor operation.⁷

A patented, wide-blade impeller features three blood flow paths. These are designed to enhance blood flow and reduce blood trauma while reducing the time blood travels through the device.⁸

THE HVAD ADVANTAGE

The HeartWare HVAD Pump is the world's smallest, full-support centrifugal VAD designed to be implanted completely within the pericardial space.

The unique integrated inflow cannula design offers the flexibility to fit into smaller framed patients and treat more complex patients. It also allows for stable inflow — even with body habitus changes eliminating complication of malposition.⁶

Easy to Implant

The small size reduces the need for a pump pocket, which may lead to decreased bleeding and decreased blood product use.⁹
The design allows for less invasive exchange and explant.⁹
A 10mm outflow graft to the artery reduces the anastomotic size by approximately 50% compared to other devices. This leads to flexibility of arterial landing sites.

Source data on file with Medtronic as of April 2017.

Lund, L, et al. For the International Society for Heart and Lung Transplantation, The Registry of the International Society for Heart and Lung Transplantation. Thirty-second Official Adult Heart Transplantation Report – 2015; Focus Theme: Early Graft Failure, J Heart Lung Transplant. 2015;34:1244-1254.

Rogers, J, et al. Intrapericardial left ventricular assist device for advanced heart failure. NEJM 2017;376:451-460.

Aaronson, KD, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation 2012;125(25): 3191–3200.

⁴

Strueber, M, et al. Multi-center evaluation of an intrapericardial left ventricular assist system. JACC 2011;57: 1375-1382.

⁵

Slaughter, M, et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transpl 2013;32: 675–683.

⁶

Sorensen EN, et al, Computed tomography correlates of inflow cannula malposition in a continuous-flow ventricular-assist-device. J Heart Lung Transpl 2013;32 (6):654-657.

⁷

LaRose, J, et al. Design concepts and principal of operation of the HeartWare Ventricular Assist System. 2010. ASAIO:285-9.

⁸

Haglund, N, et al. Perioperative blood product use: a comparison between HeartWare and HeartMate II devices. Ann Thorac Surg. 2014;9(3):842-9.

⁹

Sabashnikov, a, et al. Outcomes in patients receiving Heartmate II versus HVAD left ventricular device as a bridge to transplantation. Transplant Proc. 2014;46:1469-75.